PMC8714781_01
Patient characteristics, treatments, and outcomes. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
fimmu-12-784336-g001.jpg
PMC8714781_01_fimmu-12-784336-g001.jpg
f1
The demographic, clinical, and therapeutic details of the patients were shown in  Table 1  and  Figure 1 . The integral treatments for each patient were illustrated in  Table 1  and  Figure 1 . The images of all patients before and after CRIT were displayed in  Supplementary Figures 1-5 .
Molecular analyses of TMB (A), MSI score (B), TNB (C), and ITH (D). ITH was lower in CR than PR patients. Values were presented as median and range. Comparisons between CR and PR patients was tested using two-sided t-test. CR, complete response; CRIT, chemoradioimmunotherapy; ITH, intratumor heterogeneity; MSI, microsatellite instability; PR, partial response; TMB, tumor mutational burden; TNB, tumor neoantigen burden.
fimmu-12-784336-g002.jpg
PMC8714781_01_fimmu-12-784336-g002.jpg
f2
The images of all patients before and after CRIT were displayed in  Supplementary Figures 1-5 . Based on NGS results shown in  Figures 2A-D , the median value of TMB, MSI score, TNB and ITH were 60.48mut/Mb (range 32.31-77.18), 44.95 (range 27.45-69.06), 24.56 neos/Mb (range 5.98-40.09) and 0.116 (range 0-0.369), respectively. CR patients had a lower ITH than PR patients (p=0.019,  Figure 2D ).